Thymulin
Also known as: FTS, Facteur Thymique Sérique, Serum Thymic Factor, Zn-FTS, ZnFTS, Thymic Factor, Circulating, metFTS, methionine-FTS, methionine-serum thymic factor, PAT (peptide analogue of thymulin)
Thymic peptide hormone (nonapeptide); zinc-dependent metallopeptide; immunomodulator
What it is
Thymulin is a zinc-dependent thymic hormone studied for its anti-inflammatory and pain-relieving properties, particularly in autoimmune conditions, neuropathic pain, and lung disease. It works by regulating T-cell activity and reducing pro-inflammatory signals. No FDA-approved therapeutic use; evidence comes from animal models and early laboratory research.
The scientific side
Thymulin is a nonapeptide hormone exclusively produced by thymic epithelial cells; its biological activity requires the presence of zinc (forming Zn-FTS, the active form). It promotes intra- and extrathymic T-cell differentiation and modulates multiple T-cell subsets. Thymulin suppresses pro-inflammatory cytokine production (IL-1α, IL-1β, IL-6, TNF-α, IL-17, IFN-γ) and inhibits the NF-κB and p38 MAPK signaling pathways. It also inhibits microglial activation in the spinal cord and brain. In the context of aging and cancer, thymulin suppresses myeloid cell-driven chronic inflammation and enhances antitumor T-cell immunity. Thymulin further acts as a hypophysiotropic peptide, influencing pituitary secretion of gonadotropins, growth hormone, prolactin, and TSH, and participates in bidirectional thymus–neuroendocrine communication. Its synthetic analogue PAT (peptide analogue of thymulin) retains anti-inflammatory and analgesic properties without the hyperalgesic effects seen at low thymulin doses.
Class: Thymic peptide hormone (nonapeptide); zinc-dependent metallopeptide; immunomodulator
Administration & storage
- Administration
- Intraperitoneal (PMID: 30851702171925638582784)Intramuscular — adenoviral vector (PMID: 166173011738971428501652)Intracerebroventricular (PMID: 171925632105936028501652)Intratracheal — nanoparticle-delivered plasmid (PMID: 32577505)Intrahypothalamic or intrapituitary stereotaxic injection (PMID: 16166812)In vitro addition to cell/tissue culture (PMID: 850805012639846)Oral (homeopathic dilution 5cH in drinking waterbroiler chickens) (PMID: 22226317)
- Storage
- No storage conditions for thymulin peptide preparations are described in the reviewed abstracts.
- Cautions
- At low (ng-range) local or systemic doses, thymulin has been reported to produce hyperalgesic effects and increase pro-inflammatory mediators in animal models — dose-dependent effects appear to reverse at higher doses.,No toxicity was reported in reviewed animal studies of lung disease even at high doses or when expressed by adenoviral vectors; however, systematic safety and toxicology data in humans are absent from the reviewed literature.,Zinc is required for biological activity; zinc deficiency abolishes thymulin activity, and the zinc-unbound form is biologically inactive.,Gene therapy vectors (adenoviral, nanoparticle-based) carry platform-specific risks that are not specific to thymulin and must be evaluated separately; CK30PEG DNA nanoparticles have been reported safe in a human phase I/II clinical trial for a different gene.,No human pharmacokinetic, pharmacodynamic, or dose-finding clinical trial data for exogenous thymulin peptide administration are described in the reviewed abstracts — extrapolation from animal data is not supported.,Sterile technique is essential for any injectable preparation.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Anti-inflammatory and analgesic effects (neuropathic and inflammatory pain) Animal studies only
- Intraperitoneal thymulin reduced thermal hyperalgesia and paw edema in a CFA rat model of inflammatory pain, reduced spinal microglial activation, p38 MAPK phosphorylation, and pro-inflammatory cytokines TNF-α and IL-6. PMID 30851702 Nasseri et al., International Immunopharmacology (2019)
- Systemic injections of thymulin (1–25 µg) or PAT reduced inflammatory pain, upregulated cytokines induced by endotoxin, and alleviated sickness behavior; intracerebroventricular thymulin reduced ET-induced hyperalgesia dose-dependently and inhibited NF-κB in the hippocampus. PMID 17192563 Safieh-Garabedian et al., Annals of the New York Academy of Sciences (2006)
- ICV injection of PAT alleviated ET-induced thermal hyperalgesia, reduced body temperature elevation, and significantly decreased pro-inflammatory mediators in multiple brain regions in rats. PMID 21059360 Safieh-Garabedian et al., Neuropharmacology (2011)
- Review: PAT targets inflammatory mediators including cytokines, microglia, and possibly cholinergic mechanisms in neuropathic pain management. PMID 30503917 Safieh-Garabedian et al., Neuroscience Letters (2019)
- Immunomodulation and treatment of autoimmune/inflammatory disease (multiple sclerosis model) Animal studies only
- Thymulin improved blood-brain barrier integrity, reduced EAE symptoms, and decreased IL-6, IL-17, IFN-γ, and NF-κB activation in a mouse relapsing-remitting EAE model of multiple sclerosis. PMID 37633587 Lunin et al., Archives of Biochemistry and Biophysics (2023)
- Thymulin and PBCA nanoparticle-bound thymulin alleviated rEAE symptoms, lowered plasma cytokines, and decreased NF-κB and SAPK/JNK cascade activation; nanoparticle-bound thymulin was more effective. PMID 31671728 Lunin et al., International Journal of Molecular Sciences (2019)
- Anti-inflammatory treatment in lung disease (asthma, fetal lung) Animal studies only
- Single intratracheal dose of nanoparticle-delivered thymulin-expressing plasmid almost completely resolved established allergic asthma pathology in mice, normalizing chronic inflammation, pulmonary fibrosis, and mechanical dysregulation. PMID 32577505 da Silva et al., Science Advances (2020)
- DNA nanoparticle-delivered thymulin gene prevented lung inflammation, collagen deposition, and smooth muscle hypertrophy in a murine ovalbumin-challenged asthma model. PMID 24556417 da Silva et al., Journal of Controlled Release (2014)
- Thymulin+Zn2+ suppressed LPS-evoked TNF-α and potentiated IL-6 in fetal rat lung explants; IC50(TNF-α) ~0.5 ng/ml and EC50(IL-6) ~1.4 ng/ml in A549 cells. PMID 12639846 Land & Darakhshan, American Journal of Physiology (2004)
- Review: thymulin has consistent beneficial effects in experimental lung disease models; no toxicity reported even at high doses or when expressed by adenoviral vectors; suppresses p38 and NF-κB. PMID 20055713 Santos et al., Expert Opinion on Therapeutic Targets (2010)
- Cancer immunotherapy augmentation (age-related myeloid inflammation, anti-PD-L1 sensitization) Mixed
- Thymulin suppresses age-associated pro-inflammatory myeloid cell activation (IL-1α, IL-1β, IL-6, TNF-α) via NF-κB inhibition, enhances antitumor T-cell immunity, improves tumor control and survival, and sensitizes tumors to anti-PD-L1 therapy in aged mice in an age-dependent manner. Pro-inflammatory myeloid cells were PMID 42481458 Kanemaru et al., Nature Communications (2026)
- Type 1 diabetes (anti-inflammatory support) Animal studies only
- Thymulin reduced physiological impairments in streptozotocin-induced diabetic mice, decreased pro-inflammatory cytokines (TNF-α, IL-5, IL-17, IFN-γ), and modulated NF-κB and JNK pathways. PMID 33779346 Novoselova et al., International Journal of Immunopathology and Pharmacology (2021)
- Sepsis / chronic inflammation Animal studies only
- Free and PBCA nanoparticle-bound thymulin reduced fever, apoptosis, pro-inflammatory cytokines, Hsp72/90, TLR4, and NF-κB/MAPK/PKC-θ signaling in LPS-induced chronic inflammation in mice; nanoparticle-bound form was more effective. PMID 29795607 Novoselova et al., PLoS One (2018)
- Neuroendocrine regulation — thymus-pituitary-gonadal axis Animal studies only
- Thymulin immunoneutralization in neonatal C57BL/6 mice reduced serum gonadotropins; intramuscular adenoviral thymulin gene therapy in nude mice restored serum thymulin and prevented gonadotropin reduction. PMID 17389714 Goya et al., American Journal of Physiology (2007)
- Neonatal thymulin gene therapy in athymic nude mice restored thymulin levels, prevented ovarian dysgenesis, preserved GnRH neuron number and pituitary gonadotrope cells, and partially prevented reduction in serum estrogen. PMID 22700775 Reggiani et al., Endocrinology (2012)
- Thymic function assessment / biomarker of zinc status and thymic function Human observational
- In 93 healthy subjects, thymulin was detectable at birth, peaked in children aged 5–10 years, declined from adolescence, reached lowest values by age 36, and remained steady until age 80. PMID 10971509 Consolini et al., Clinical and Experimental Immunology (2000)
- RIA measured thymulin in umbilical blood (2191±123 fg/ml), children/adults up to 20 years (1499±119 fg/ml), adults 21–65 years (371±18 fg/ml); no thymulin detected in nude rats, nude mice, or thymectomized mice. PMID 2313103 Safieh et al., Journal of Immunological Methods (1990)
- In 290 children (9–13 years) in Nepal, geometric mean thymulin was 1.37 ng/ml; positively associated with gestational age, height, and maternal β-carotene supplementation; lower pre-monsoon and monsoon seasons. PMID 31475652 Palmer et al., Journal of Developmental Origins of Health and Disease (2020)
- Serum thymulin activity was decreased in mild human zinc deficiency (even with normal plasma zinc) and restored by in vivo and in vitro zinc supplementation. PMID 3262625 Prasad et al., Journal of Clinical Investigation (1988)
- HIV and opportunistic infections (zinc-thymulin axis) Human observational
- Active zinc-bound thymulin (ZnFTS) was strongly reduced in HIV stage IV with concomitant CD4+ depletion; zinc supplementation (45 mg Zn2+/day for 1 month) with AZT restored active thymulin and CD4+ cells and reduced recidivism opportunistic infections by 50%. PMID 10801955 Mocchegiani & Muzzioli, Journal of Nutrition (2000)
- Inflammatory cytokine modulation in systemic lupus erythematosus In vitro only
- In vitro thymulin at 1,000 ng/ml significantly inhibited TNF-α in both healthy volunteers and SLE patients; inhibited IL-6 in volunteers at all doses tested; inhibited IL-1α in SLE patients; inhibited IL-2 only in SLE patients at 1,000 ng/ml. PMID 8508050 Safieh-Garabedian et al., International Archives of Allergy and Immunology (1993)
- Primary open-angle glaucoma (observational plasma levels) Human observational
- Plasma thymulin levels were significantly elevated (p<0.001) in 28 newly diagnosed, untreated POAG patients compared to age/sex-matched controls; role in pathogenesis remains unclear. PMID 16217660 Noureddin et al., Graefe's Archive (2006)
- Protein-energy malnutrition / nutritional deficiency (thymic function biomarker) Human observational
- Thymulin content of thymus glands was very low in Senegalese children dying of severe malnutrition (marasmus, kwashiorkor); thymic zinc content was unrelated to nutritional state but related to infections. PMID 3136643 Jambon et al., American Journal of Clinical Nutrition (1988)
- Specific plasma thymulin activity was almost undetectable in infected malnourished Senegalese children and reduced even by moderate PEM; concurrent infections were identified as important additional factors. PMID 3124594 Wade et al., American Journal of Clinical Nutrition (1988)
- GH deficiency and thymic endocrine function Human observational
- Children and adults with GH deficiency had significantly reduced active and total thymulin; 3–6 months of recombinant GH therapy significantly increased both active and total thymulin to levels comparable to controls. PMID 8957749 Mocchegiani et al., Journal of Endocrinological Investigation (1996)
- Gene therapy for chronic inflammatory and neuroendocrine disorders Animal studies only
- Single i.m. injection of RAd-metFTS (10^7 PFU/mouse or 10^8 PFU/rat) in thymectomized animals restored serum thymulin levels for at least 110 days (mice) and 130 days (rats) post-injection. PMID 16617301 Reggiani et al., Gene Therapy (2006)
- A bidirectional regulatable Tet-Off two-adenovector system expressed thymulin in vivo; intracerebroventricular injection raised CSF thymulin; intramuscular injection progressively raised serum thymulin; doxycycline inhibited expression. PMID 28501652 Zappa-Villar et al., Molecular Immunology (2017)
Safety signals
- Hyperalgesic effect at low (ng) local (intraplantar) or systemic (intraperitoneal) doses in animal models, with increased pro-inflammatory mediators; this effect was not observed with the analogue PAT or at higher doses. PMID 17192563
- Dose-dependent biphasic effects on cytokines: low doses (1 ng/ml) increased IL-1α in healthy volunteers in vitro, while higher doses inhibited it; effects differ between healthy individuals and SLE patients. PMID 8508050
- Thymulin levels were significantly elevated in patients with primary open-angle glaucoma compared to controls, suggesting a possible pathogenic role; however, causality was not established. PMID 16217660
- No toxicity reported in animal models of lung disease even at high doses or when delivered by adenoviral vectors, though systematic preclinical toxicology is not described in reviewed literature. PMID 20055713
Contraindications
- No contraindications are explicitly stated in the reviewed abstracts for exogenous thymulin administration. PMID 20055713
Protocol
No community dose for Thymulin on record yet.
All studies (31)
- PMID 2313103 Human observational
Thymic function assessment / biomarker of zinc status and thymic function - PMID 3124594 Human observational
Protein-energy malnutrition / nutritional deficiency (thymic function biomarker) - PMID 3136643 Human observational
Protein-energy malnutrition / nutritional deficiency (thymic function biomarker) - PMID 3262625 Human observational
Thymic function assessment / biomarker of zinc status and thymic function - PMID 8957749 Human observational
GH deficiency and thymic endocrine function - PMID 10801955 Human observational
HIV and opportunistic infections (zinc-thymulin axis) - PMID 10971509 Human observational
Thymic function assessment / biomarker of zinc status and thymic function - PMID 16217660 Human observational
Primary open-angle glaucoma (observational plasma levels) - PMID 31475652 Human observational
Thymic function assessment / biomarker of zinc status and thymic function - PMID 42481458 Mixed
Cancer immunotherapy augmentation (age-related myeloid inflammation, anti-PD-L1 sensitization) - PMID 56
Immunoneutralization: i.p. injections of rabbit anti-thymulin serum from postnatal day 1–35; gene therapy: single bilateral i.m. injection of RAd-FTS on postnat - PMID 8508050 In vitro only
Inflammatory cytokine modulation in systemic lupus erythematosus - PMID 8582784
100 ng/day × 5 days (zinc-thymulin) Intraperitoneal (animal) - PMID 12639846 Animal studies only
Anti-inflammatory treatment in lung disease (asthma, fetal lung) - PMID 16166812
Not specified (saline or thymulin injected into hypothalamic nuclei or pituitary) Intrahypothalamic (anterior or medial) or intrapituitary injection (animal) - PMID 16617301 Animal studies only
Gene therapy for chronic inflammatory and neuroendocrine disorders - PMID 17192563 Animal studies only
Anti-inflammatory and analgesic effects (neuropathic and inflammatory pain) - PMID 17389714 Animal studies only
Neuroendocrine regulation — thymus-pituitary-gonadal axis - PMID 20055713 Animal studies only
Anti-inflammatory treatment in lung disease (asthma, fetal lung) - PMID 21059360 Animal studies only
Anti-inflammatory and analgesic effects (neuropathic and inflammatory pain) - PMID 22226317
- PMID 22700775 Animal studies only
Neuroendocrine regulation — thymus-pituitary-gonadal axis - PMID 24556417 Animal studies only
Anti-inflammatory treatment in lung disease (asthma, fetal lung) - PMID 28501652 Animal studies only
Gene therapy for chronic inflammatory and neuroendocrine disorders - PMID 29795607 Animal studies only
Sepsis / chronic inflammation - PMID 30503917 Animal studies only
Anti-inflammatory and analgesic effects (neuropathic and inflammatory pain) - PMID 30851702 Animal studies only
Anti-inflammatory and analgesic effects (neuropathic and inflammatory pain) - PMID 31671728 Animal studies only
Immunomodulation and treatment of autoimmune/inflammatory disease (multiple sclerosis model) - PMID 32577505 Animal studies only
Anti-inflammatory treatment in lung disease (asthma, fetal lung) - PMID 33779346 Animal studies only
Type 1 diabetes (anti-inflammatory support) - PMID 37633587 Animal studies only
Immunomodulation and treatment of autoimmune/inflammatory disease (multiple sclerosis model)